ALK+ Non-Small-Cell Lung Carcinoma
1 clinical trials · Condition
◉ Watch ALK+ Non-Small-Cell Lung Carcinoma
| Record | Firm | Date |
|---|---|---|
| Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context (NCT06487078) | Pfizer | 2025-01-20 |
Track ALK+ Non-Small-Cell Lung Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.